Key facts
- Ataraxis (Diagnostic Equipment)’s last known valuation is $68.0M (Mar 2025).
- It has raised $24.1M; the latest was Early Stage VC ($20.0M) in Mar 2025.
- Notable investors include Transpose Platform Management, Founders Fund, Endless Frontier Labs, AIX Ventures, Obvious Ventures — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Ataraxis (Diagnostic Equipment)
- ·The full record, as it builds
Funding rounds
No funding rounds for Ataraxis (Diagnostic Equipment) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ataraxis (Diagnostic Equipment)
Developer of prognostic and predictive digital diagnostic assays designed to help doctors select the optimal treatment for all patients. The company integrates multi-modal data to deliver accurate, patient-specific predictions about therapeutic outcomes across several diseases, enabling doctors to detect the early stage of breast cancer.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2022
- Employees
- 29
- Website
- ataraxis.ai/
- Ownership
- Privately Held (backing)
Ataraxis (Diagnostic Equipment) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ataraxis (Diagnostic Equipment) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ataraxis (Diagnostic Equipment) in its N-PORT filings yet. We sweep new filings monthly.